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Abstract 
The association between primary biliary cirrhosis (PBC) and autoimmune hemolytic 
anemia (AIHA) is uncommon; only fourteen such case reports have been described. In 
this report, three patients who developed AIHA on the basis of PBC underwent successful 
therapy with corticosteroids and ursodeoxycholic acid (UDCA). Patient 3 was more 
complicated, suffering from PBC, Evans syndrome, Sjögren syndrome and Klinefelter 
syndrome simultaneously. This has not previously been reported in the world literature. 
Review of all fifteen cases showed that there is a prominent occurrence sequence that 
AIHA might take place on the basis of PBC. With sufficient doses of corticosteroids or 
immunosuppressant therapy, besides hemolysis under effective control, liver function 
also improved. According to the criteria of secondary AIHA, we may call them 
PBC-related AIHA. Thus, patients with PBC with serum bilirubin levels rising suddenly 
should undergo screening for associated hemolysis. Recommended treatment for 
PBC-related AIHA includes sufficient doses of corticosteroids to control the hemolysis in 
the acute phase, and immunosuppressant or adequate dose of UDCA to maintain 
therapy. These case reports have been increasing in recent years, so further reserch is 
needed to illustrate the incidence and natural courses of these two organ-specific 
autoimmune diseases. 
 
Introduction 
Although the etiology of primary biliary cirrhosis (PBC) is unclear, it is probably 
related to altered immunoregulation [1]. Autoimmune hemolytic anemia (AIHA) is 
characterized by a positive direct Coombs’ test. It is idiopathic (primary) in  
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approximately 50% cases or secondary to medication, hematological malignancies and 
autoimmune disorders [2].The association between PBC and other autoimmune diseases 
has been reported, mostly including rheumatoid arthritis, Sjögren syndrome, 
scleroderma, and so on [3]. However, the association between PBC and AIHA is 
uncommon. To our knowledge, only fourteen such case reports have been described in 
the world literature [4–17]. We now describe the cases of three such patients. 
Patient 1 
A 74-year-old woman was admitted to our hospital in December 2006, with a history of fatigue, 
anorexia and jaundice for about one month. Her past medical history included hypertension and 
hyperlipidemia diagnosed at ages 44 and 54. She was a nondrinker but a smoker. On admission, 
physical examination revealed mild jaundice, conjunctival pallor and peripheral edema, 
hepatosplenomegaly and ascites. Laboratory data revealed severe anemia: hemoglobin (Hb) 6.1 g/dl 
(range 13.7–17.9 g/dl); white blood cell count (WBC) and blood platelet count (PLT) were normal. 
Reticulocyte (RET) was increased at 4.77% (range 1.0–2.5%). Stool occult blood test was negative. Liver 
function test: ALT and AST were both in normal range; total serum bilirubin (T-bil) 47.5 mg/l (range 1–
10 mg/l); direct serum bilirubin (D-bil) 7.7 mg/l (range 1–4 mg/l); albumin 29 g/l (range 35–50 g/l); 
alkaline phosphatase (ALP) 186 IU/l (range 40–160 IU/l); γ-glutamyltranspeptidase (γ-GT) 127 IU/l 
(range 0–50 IU/l). Hepatitis B surface antigen and antibody to hepatitis C virus were both negative. 
Ultrasonography showed hepatosplenomegaly, ascites and multiple stones in the gallbladder. Coombs’ 
test was performed and it was positive for anti-IgG. The bone marrow aspirate showed erythroid 
hyperplasia obviously with ripe erythrocytes polychromasia and inequality of size. Serum 
immunoglobulin M (IgM) 5.44 g/l (range 0.63–2.77 g/l); immunoglobulin G (IgG) 22.10 g/l (range 
7.23–16.85 g/l); immunoglobulin A (IgA) 3.41 g/l (range 0.69–3.82 g/l); antinuclear antibody (ANA) 
1:1000, antimitochondrial antibody (AMA) 1:1000, M2 subtype positive. On this basis PBC combined 
with AIHA was diagnosed. 
Prednisolone (PSL) 60 mg and ursodeoxycholic acid (UDCA) 750 mg (12.5 mg/kg) daily were given. 
At the same time, the patient was commenced on high dosages of intravenous immunoglobulin (20 g 
daily) for 5 days, spironolactone 60 mg, furosemide 20 mg and a daily 1 litre fluid restriction. This 
resulted in 3 kg weight loss with noticeable improvement in her ascites and peripheral edema. Her 
anemia responded to PSL quickly. Three weeks after initiation of therapy, her Hb level had recovered to 
9.1 g/dl, RET to 1.84%, and liver function had improved: albumin 35.1 g/l; ALP 53 IU/l; γ-GT 42 IU/l. 
PSL was then gradually tapered and UDCA continued with the same dosage. Tow months later, her Hb 
had risen to 11.6 g/dl. During one-year follow-up her Hb was stable and PSL 10 mg and UDCA 750 mg 
daily were continued. 
Patient 2 
A 60-year-old man was admitted to our hospital in March 2007 with a 2-year history of progressive 
fatigue and anorexia. He had a small quantity of alcohol consumption (ethanol ᧸25 g per week). On 
admission, physical examination revealed neither jaundice nor xanthelasma, but mild splenomegaly and 
conjunctival pallor. Laboratory data revealed the following: Hb 5.4 g/dl; RET 1.18%; WBC and PLT 
were in normal range. ALT, AST, T-bil, D-bil were all normal. ALP 128 IU/l; γ-GT 110 IU/l. Hepatitis B 
surface antigen and antibody to hepatitis C virus were both negative. Stool occult blood test was 
negative. Elevated level of IgM, 3.58 g/l was noted, but IgG and IgA were normal. ANA and AMA were 
both positive at a titer of 1:1000, and AMA M2, M4 subtype were both positive. Abdominal 
ultrasonography revealed mild splenomegaly. The bone marrow aspirate showed erythroid hyperplasia 
obviously with ripe erythrocytes polychromasia and inequality of size. Blood transfusion with packed 
red blood cell was instituted for cardiorespiratory distress relief. However, after transfusion his Hb 
descended to 5.1 g/dl and RET to 6.39%; Coombs’ test was performed, and the outcome was positive for 
anti-IgG. He was diagnosed as PBC combined with AIHA. 
The patient was treated with PSL 60 mg and UDCA 750 mg (12 mg/kg) daily. His anemia responded 
to this treatment. Three weeks after initiation of therapy, his Hb level had recovered to 8.0 g/dl, RET to 
2.36%, and his liver function had improved: ALP 45 IU/l; γ-GT 63 IU/l. After 3 months of this therapy 
his Hb had risen to 12.2 g/dl with a normal liver function. During a one-year period, PSL was gradually 
tapered to 10 mg per day and UDCA was continued. A year later, in April 2008, liver needle biopsy was  
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performed; the outcome showed mild aggregates of lymphoid cells and fibrosis in the portal area, and 
the bile ducts were scanty. The lumens of the residual bile ducts were irregular. The pathologic findings 
were compatible with PBC. 
Patient 3 
A 55-year-old man was admitted to our hospital in May 2008, with a 4-month history of fatigue. His 
past medical history included: PBC, immune thrombocytopenia purpura (ITP), Sjögren syndrome and 
Klinefelter syndrome. In 2002 health examination had revealed that he had thrombocytopenia (PLT 
10 × 10
9/l) and splenomegaly. Platelet-associated IgG (PAIgG) and antiphospholipid antibody were 
strongly positive. Bone marrow examination revealed increased megakaryocytes without any other 
significant findings. Chromosome karyotyping analysis showed 47XXY. Liver biopsy was performed 
and the specimen showed moderate to generous aggregates of plasmacytes and lymphocytes with mild 
piecemeal necrosis and lobular disorganization. AMA and M2 subtype were both positive. Excessive 
dryness of mouth and eyes were other symptoms of this patient. Schirmer’s test, saliva flow rate and 
biopsy of salivary gland were performed, and the outcomes were compatible with Sjögren syndrome. 
Thus, PBC, ITP, Sjögren syndrome and Klinefelter syndrome were diagnosed.  
UDCA (8.5 mg/kg) was given combined with prednisone 40 mg daily. After one month of therapy 
his PLT rose to 50–60 × 10
9/l. Prednisone was intermittently used and thrombocytopenia was partially 
controlled. In February 2004, he had splenectomy. After the operation cyclophosphamide (CTX), 
azathioprine (AZA) or cyclosporine A (CsA) were successively used.  
In January 2008, because of extremely fatigue he came to our hospital. On admission, physical 
examination revealed pallid conjunctiva, rampant caries and testicular maldevelopment. Laboratory 
data revealed: Hb 5.8 g/dl, PLT 5 × 10
9/l, RET 3.6%. Stool occult blood tests were negative two times. 
Liver function tests were normal. ANA 1:1000. PAIgG was positive; Coombs’ test was positive for 
anti-IgG. PBC combined with Evans syndrome, Klinefelter syndrome and Sjögren syndrome were 
diagnosed. UDCA 600 mg daily did not adjust, but PLS 60 mg daily was added, and daily CsA 200 mg 
intravenous injection was given for continuous three days. After three days, CsA 100 mg daily was given 
orally. Three weeks after the treatment, the patient felt that fatigue was ameliorated obviously. Hb had 
risen to 8.6 g/dl, PLT to 20 × 10
9/l, and RET to 2.06%. 
Discussion 
PBC is a slowly progressive autoimmune disease. The diagnosis of PBC is based on 
three criteria: elevation of liver enzymes (most commonly ALP and γ-GT), presence of 
detectable AMA in the serum, and liver histologic findings that are compatible with the 
presence of the disease [18]. While AIHA is also an immune disease which is caused by 
antibodies directed against autologous red cells, the diagnosis is based on the presence of 
anemia, signs of hemolysis with reticulocytosis, increased lactate dehydrogenase, elevated 
indirect bilirubin, and a positive Coombs’ test [2]. 
The association between PBC and AIHA is uncommon. Only fourteen such case 
reports have been described. All these fourteen cases reported previously with an 
association of PBC and AIHA are summarized in table 1 and table 2. Because of language 
barrier, we could not obtain data from two of the reports, so 12 reports (15 patients) are 
summarized. 
For those patients combining PBC with AIHA, it is puzzling that besides the liver, the 
immune attack focuses on red blood cells, where mitochondrial autoantigens are not 
found. Is the association a coincidence? Searching PubMed and using ‘autoimmune 
hemolytic anemia’ and ‘liver cirrhosis’, only 25 articles were found in last 30 years. 
Although PBC is not a common cause of liver cirrhosis, most of the articles are about PBC 
in combination with AIHA. Does this indicate that PBC patients have the 
pathophysiological foundations for AIHA occurrence?  
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Another interesting thing is that none of the 18 patients suffered from AIHA before 
PBC was diagnosed. Although the two conditions were detected at the same time in some 
of the patients, not all patients with PBC received the diagnosis when it was at an early 
stage because of their asymptomatic status [19], and it is supposed that AIHA occurred 
after PBC development in these patients. The occurrence suggests a possible relationship 
between the two diseases. PBC patients are likely to have some conditions which can 
induce generation of anti-erythrocyte antibodies [8]. 
With sufficient corticosteroids or immunosuppressant therapy, hemolysis control in 
these PBC patients achieves a very good treatment effect (table 2). Hemolysis was 
controlled. In addition, liver function was improved in all of the 16 patients who had been 
successfully treated. Corticosteroid treatment is not only a preferred therapy for AIHA, 
but an adjuvant therapy that benefits PBC patients [20]. According to the criteria of 
secondary AIHA [2]: (1) AIHA would occur on the basis of PBC; (2) reversal of AIHA 
and liver function improvement of PBC happened simultaneously with the intake of 
immunosuppressive agents; (3) both PBC and AIHA are known to be immune-mediated 
diseases. Thus, we could call them PBC-related AIHA. 
Serum bilirubin levels have long been known to be important in assessing the 
prognosis of PBC, but confounding hemolysis may lead to erroneous conclusions about 
the severity of PBC. At the same time, compared with primary AIHA, this PBC-related 
AIHA is life-threatening but can be controlled. If no attention is paid to this condition, 
primary PBC will be ignored, as 50–60% of PBC patients are asymptomatic at diagnosis 
[21]. Therefore patients with PBC whose serum bilirubin levels rise suddenly should 
undergo screening for associated hemolysis. 
The recommended treatment for PBC-related AIHA includes sufficient doses of 
corticosteroids to control the hemolysis at the acute phase, and immunosuppressant (for 
example CTX and CsA) or adequate dose of UDCA to maintain therapy. To deal with the 
severe, life-threatening hemolysis, intravenous immunoglobulin and large dosage of 
corticosteroids impact therapy may be considered. Only UDCA therapy for PBC patients 
with mild AIHA had a successful report [8], so in mild cases this method could be 
considered with regular blood cell counts to monitor response. Although Kaibori et al. [5] 
provided a successful case that could confirm liver transplantation and splenectomy is a 
curative therapy to PBC-related AIHA, as Retana et al. [6] reported, hemolysis also 
occurred after liver transplantation despite well-functioning graft. So immunosuppressant 
prescribed after liver transplantation and splenectomy would not avoid further 
production of anti-erythrocyte antibodies in all of the cases. Other immunosuppressants, 
for example rituximab (anti-CD20), appear to be highly effective in patient with warm 
antibody AIHA that is refractory to standard therapy. So it will become a potential 
treatment for PBC-related AIHA, which is refractory to the above treatment. 
As illustrated in table 1, case reports have been growing in number in recent years. If 
our three case reports are added, in the last 8 years (since 2000) there have been 13 cases 
(13/18) reported. Thus, further research is required for illustrating the incidence and 
natural courses of these two organ-specific autoimmune diseases. 
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Table 1. Characteristics of PBC-related AIHA cases reported in the world literature 
Authors Country  No.  of 
patients 
Sex Race  Onset  age 
PBC/AIHA 
Liver 
pathology 
Coombs’ test  AMA/ 
ANA 
Nadir 
Hb 
Azad et al., 2007 
[4] 
Australia 1  f  Australian 81/83  * +; 
warm-type 
+/– 66  g/l 
Kaibori et al.,  
2007 [5] 
Japan 1  f  Japanese  38/49  PBC  III  C3+ IgM+; 
cold-type 
+/– 45  g/l 
Retana et al., 2007 
[6] 
USA 3  f  American  43/62/65
Δ  ***   IgG+; 
warm-type 
*/* 23%** 
     m    49/54/59
Δ  *** C 3+ IgG+; 
warm-type 
*/* 24%** 
     m    43/47/59
Δ  *** +;  warm-type  */* 25%** 
Cantalapiedra et 
al., 2005 [7] 
Spain 1  f  Spanish  50/50  PBC  I/II  C3+ IgG+; 
warm-type 
 71  g/l 
Fuller et al., 2003 
[8] 
Australia 1  f  Australian 58/62  PBC  III  C3+ IgG+; 
warm-type 
+/* 91  g/l 
Nakasone et al., 
2000 [9] 
Japan  1  f  Japanese  68/68  PBC III   C3+ IgG+; 
warm-type 
–/+ 63  g/l 
Brackstone and 
Ghent, 2000 [10] 
Canada 2  f 
f 
Canadian 49/58 
66/68 
PBC IV 
PBC III 
cold-type 
warm-type 
+/* 
+/* 
82 g/l 
58 g/l 
Chen et al., 1997 
[11] 
Taiwan  1  f Taiwan 49/49    mix-type  +/+ 63  g/l 
Yoshida et al., 
1996 [13] 
Canada 1  m Indian  66/66  PBC  I  C3+ IgG+; 
warm-type 
+/– 59  g/l 
Shichiri et al., 
1984 [14] 
Japan 1  f  Japanese  32/32  *** C 3+ IgG+; 
warm-type 
+/– 32  g/l 
Orlin et al., 1980 
[16] 
USA 1  f  American  51/57 *** C 3+; 
cold-type 
+/– 23%** 
Hume et al., 1970 
[17] 
England 1  f  English  50/50  *** +; 
warm-type 
+/* 68  g/l 
* Not performed or mentioned. ** Hematocrit. *** Compatible with PBC. 
Δ The second number was the age at liver 
transplantation 
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Table 2. Treatment of PBC-related AIHA cases reported in the world literature 
Authors Initiated  cortico- 
steroid dosage 
Hb response to 
corticosteroids 
Other therapies to treat AIHA   Prognosis 
Azad et al., 2007 
[4] 
PSL 50 mg/day p.o.  very good*  AZA to maintain therapy    11 months
follow-up 
stable 
Kaibori et al., 
2007 [5] 
Did not use    immunosuppressant post 
liver transplantation 
 1  year 
follow-up 
stable 
Retana et al., 
2007 [6] 
Methylprednisolone 
60 mg/day i.v. 
very good*  rituximab and previous 
immunosuppressant for liver 
transplantation (taccrolimus 
and UDCA) were used to 
maintain therapy 
 4  months 
follow-up 
stable 
 methylprednisolone 
100 mg/day i.v. 
did not improve 
for 3 days 
intravenous immunoglobulin 
was administered, then the 
patient improved 
 8  months 
follow-up 
stable 
  did not use        died 
Cantalapiedra et 
al., 2005 [7] 
prednisone 
1 mg/kg p.o. 
very good*  UDCA 15 mg/kg was also 
administered to the patient 
  
Fuller et al., 2003 
[8] 
did not use    only UDCA was used; very 
good response 
 1  year 
follow-up 
stable 
Nakasone et al., 
2000 [9] 
PSL 60 mg/day p.o.  very good*  liver function was worsening 
during the prednisolone 
tapering phase, UDCA was 
added to maintain therapy 
 1  year 
follow-up 
stable 
Brackstone and 
Ghent, 2000 [10] 
prednisone 
50 mg/day p.o. 
very good*  at the same time, UDCA 
1 g/day was also added to the 
patient 
 1  year 
follow-up 
stable 
 prednisone 
20 mg/day p.o. 
  AZA to maintain therapy    3 years 
follow-up 
stable 
Chen et al., 1997 
[11] 
methylprednisolone 
900 mg/day i.v. 
very good*  at the corticosteroids tapering 
phase, UDCA was added to 
maintian therapy 
  ** 
Yoshida et al., 
1996 [13] 
prednisone 
125 mg/day p.o. 
(2 mg/kg) 
very good*     7  months 
follow-up 
stable 
Shichiri et al., 
1984 [14] 
methylprednisolone 
1,326 mg/day i.v. 
very good*     *** 
Orlin et al., 1980 
[16] 
did not use    plasma exchange    died 
Hume et al., 1970 
[17] 
not mentioned in 
the report 
very good*     ** 
*
 Very good means hemolysis was controlled rapidly. **
 Follow-up time not mentioned in the report, 
but the patient was discharged in good condition. ***
 Two months follow-up stable, then tiopronin was 
given and adverse reaction presented. 
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